Skip to main content
Premium Trial:

Request an Annual Quote

Lab21 to Distribute AdnaGen's Assays in UK, Ireland

NEW YORK (GenomeWeb News) – Lab21 will serve as exclusive distributor of AdnaGen's circulating tumor cell diagnostic assays in the UK and Ireland under an alliance announced today.

AdnaGen's AdnaTest products detect and analyze circulating tumor cells from metastatic breast cancer and metastatic colon cancer. According to the firms, AdnaGen's tests enable detection of a broad range of tumor molecular markers.

Cambridge, UK-based Lab21 said that it expects to launch the tests as a service beginning in October.

"Detecting circulating tumor cells provides physicians a means to monitor therapy," Berwyn Clarke, Chief Scientific Officer of Lab21, said in a statement. "Since cancer is evolving from a fatal condition towards a chronic disorder, Lab21 wants to position itself to offer tools for improved patient management as well as cost control. We also see this as a key new service to offer our pharmaceutical partners as they develop new anti-cancer agents."

Financial and other terms of the alliance were not disclosed.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.